US20130261113A1 - Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis - Google Patents
Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis Download PDFInfo
- Publication number
- US20130261113A1 US20130261113A1 US13/908,566 US201313908566A US2013261113A1 US 20130261113 A1 US20130261113 A1 US 20130261113A1 US 201313908566 A US201313908566 A US 201313908566A US 2013261113 A1 US2013261113 A1 US 2013261113A1
- Authority
- US
- United States
- Prior art keywords
- methoxy
- dihydroimidazo
- quinazolin
- morpholin
- ylpropoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 [1*]OC1=CC=C2C3=NCCN3C(NC([2*])=O)=NC2=C1O[3*] Chemical compound [1*]OC1=CC=C2C3=NCCN3C(NC([2*])=O)=NC2=C1O[3*] 0.000 description 22
- VMNRHLODALCDML-UHFFFAOYSA-N CCC1CN(CCCCl)CCO1 Chemical compound CCC1CN(CCCCl)CCO1 VMNRHLODALCDML-UHFFFAOYSA-N 0.000 description 2
- BEMUPKPURPXIOV-UHFFFAOYSA-N CCCC1=NC(N)=NC=C1C(=O)NC1=NC2=C(OC)C(OCCCN3CCOCC3)=CC=C2C2=NCCN12 Chemical compound CCCC1=NC(N)=NC=C1C(=O)NC1=NC2=C(OC)C(OCCCN3CCOCC3)=CC=C2C2=NCCN12 BEMUPKPURPXIOV-UHFFFAOYSA-N 0.000 description 2
- WJTQKNQTKYYWRW-UHFFFAOYSA-N CCN1CCOC(CCOC2=CC=C3C4=NCCN4C(NC(=O)C4=CC=CN=C4)=NC3=C2OC)C1 Chemical compound CCN1CCOC(CCOC2=CC=C3C4=NCCN4C(NC(=O)C4=CC=CN=C4)=NC3=C2OC)C1 WJTQKNQTKYYWRW-UHFFFAOYSA-N 0.000 description 2
- PZBCKZWLPGJMAO-UHFFFAOYSA-N COC1=C2/N=C(/NC(=O)C3=CN=C(N)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2/N=C(/NC(=O)C3=CN=C(N)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 PZBCKZWLPGJMAO-UHFFFAOYSA-N 0.000 description 2
- ZYVGMXTZLDVOIW-UHFFFAOYSA-N COC1=C2N=C(N)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(N)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 ZYVGMXTZLDVOIW-UHFFFAOYSA-N 0.000 description 2
- ABYVJGMYXVHJSH-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=C(C)N=C3)N3CCN=C3C2=CC=C1OCCN(C)C Chemical compound COC1=C2N=C(NC(=O)C3=CC=C(C)N=C3)N3CCN=C3C2=CC=C1OCCN(C)C ABYVJGMYXVHJSH-UHFFFAOYSA-N 0.000 description 2
- LQLQKCGNICXNHX-FQEVSTJZSA-N COC1=C2N=C(NC(=O)C3=CC=C(N4CC[C@H](N)C4)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1.Cl Chemical compound COC1=C2N=C(NC(=O)C3=CC=C(N4CC[C@H](N)C4)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1.Cl LQLQKCGNICXNHX-FQEVSTJZSA-N 0.000 description 2
- JHXNHMRUEXSBOO-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=C(NC(=O)NC(C)C)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CC=C(NC(=O)NC(C)C)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 JHXNHMRUEXSBOO-UHFFFAOYSA-N 0.000 description 2
- UBBRJCAEAQHSFR-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=C(NC(C)=O)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CC=C(NC(C)=O)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 UBBRJCAEAQHSFR-UHFFFAOYSA-N 0.000 description 2
- YTWYXKYMMKOBOM-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCC(O)CN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCC(O)CN1CCOCC1 YTWYXKYMMKOBOM-UHFFFAOYSA-N 0.000 description 2
- CLTOGHIOSYMIGR-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCC1CN(C)CCO1 Chemical compound COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCC1CN(C)CCO1 CLTOGHIOSYMIGR-UHFFFAOYSA-N 0.000 description 2
- PFAXMTRQGWBENF-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCCCN1CCOC(CO)C1 Chemical compound COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCCCN1CCOC(CO)C1 PFAXMTRQGWBENF-UHFFFAOYSA-N 0.000 description 2
- PCFYSQDMKAZAGR-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCCCN1CCOC(OC)C1 Chemical compound COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCCCN1CCOC(OC)C1 PCFYSQDMKAZAGR-UHFFFAOYSA-N 0.000 description 2
- WNUPSDDMPRHUPR-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCCN(C)C Chemical compound COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCCN(C)C WNUPSDDMPRHUPR-UHFFFAOYSA-N 0.000 description 2
- ZIDFUBHWWUXLRT-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CN=C(N4CCOCC4)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CN=C(N4CCOCC4)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 ZIDFUBHWWUXLRT-UHFFFAOYSA-N 0.000 description 2
- MYZQRTALORWOFJ-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CN=CN=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CN=CN=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 MYZQRTALORWOFJ-UHFFFAOYSA-N 0.000 description 2
- FYGKNFXODIEWJB-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=C[N+]([O-])=CC=C3)N3CCN=C3C2=CC=C1OCCCN(C)C Chemical compound COC1=C2N=C(NC(=O)C3=C[N+]([O-])=CC=C3)N3CCN=C3C2=CC=C1OCCCN(C)C FYGKNFXODIEWJB-UHFFFAOYSA-N 0.000 description 2
- LIFRIQMZAJHJHJ-UHFFFAOYSA-N COCCN1CCOC(CCCOC2=CC=C3C4=NCCN4C(NC(=O)C4=CC=CN=C4)=NC3=C2OC)C1 Chemical compound COCCN1CCOC(CCCOC2=CC=C3C4=NCCN4C(NC(=O)C4=CC=CN=C4)=NC3=C2OC)C1 LIFRIQMZAJHJHJ-UHFFFAOYSA-N 0.000 description 2
- VUDVZUAUPOAVLM-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCOC(CCO)C1 Chemical compound CC(C)(C)OC(=O)N1CCOC(CCO)C1 VUDVZUAUPOAVLM-UHFFFAOYSA-N 0.000 description 1
- TZZLIARCVQOPQS-UHFFFAOYSA-N CC1=NC(N)=CC=C1C(=O)O Chemical compound CC1=NC(N)=CC=C1C(=O)O TZZLIARCVQOPQS-UHFFFAOYSA-N 0.000 description 1
- HURDYUYGVKPKSO-UHFFFAOYSA-N CCC(=O)CC1=NC(C(=O)NC2=NC3=C(OC)C(OCCCN4CCOCC4)=CC=C3C3=NCCN23)=CS1 Chemical compound CCC(=O)CC1=NC(C(=O)NC2=NC3=C(OC)C(OCCCN4CCOCC4)=CC=C3C3=NCCN23)=CS1 HURDYUYGVKPKSO-UHFFFAOYSA-N 0.000 description 1
- GKYNPZZGDJPLSR-UHFFFAOYSA-N CCC1=NC(C(=O)NC2=NC3=C(OC)C(OCCCN4CCOCC4)=CC=C3C3=NCCN23)=CS1 Chemical compound CCC1=NC(C(=O)NC2=NC3=C(OC)C(OCCCN4CCOCC4)=CC=C3C3=NCCN23)=CS1 GKYNPZZGDJPLSR-UHFFFAOYSA-N 0.000 description 1
- ROOSLCGRZRWZSJ-UHFFFAOYSA-N CCC1CN(CCCOC2=CC=C3C4=NCCN4C(NC(=O)C4=CC=CN=C4)=NC3=C2OC)CCO1 Chemical compound CCC1CN(CCCOC2=CC=C3C4=NCCN4C(NC(=O)C4=CC=CN=C4)=NC3=C2OC)CCO1 ROOSLCGRZRWZSJ-UHFFFAOYSA-N 0.000 description 1
- RGNFMQJLAOONTP-UHFFFAOYSA-N CCC1CNCCO1 Chemical compound CCC1CNCCO1 RGNFMQJLAOONTP-UHFFFAOYSA-N 0.000 description 1
- FYGIAJGIHGLMOC-UHFFFAOYSA-N CCCC1=NC(N)=NC=C1C(=O)O Chemical compound CCCC1=NC(N)=NC=C1C(=O)O FYGIAJGIHGLMOC-UHFFFAOYSA-N 0.000 description 1
- AITFHDROVDHPHJ-UHFFFAOYSA-N CCN(CC)CCCOC1=CC=C2C3=NCCN3C(NC(=O)C3=CC=CN=C3)=NC2=C1OC Chemical compound CCN(CC)CCCOC1=CC=C2C3=NCCN3C(NC(=O)C3=CC=CN=C3)=NC2=C1OC AITFHDROVDHPHJ-UHFFFAOYSA-N 0.000 description 1
- UUMDZEMRXJMVLW-UHFFFAOYSA-N CCN(CC)CCOC1=CC=C2C3=NCCN3C(NC(=O)C3=CC=CN=C3)=NC2=C1OC Chemical compound CCN(CC)CCOC1=CC=C2C3=NCCN3C(NC(=O)C3=CC=CN=C3)=NC2=C1OC UUMDZEMRXJMVLW-UHFFFAOYSA-N 0.000 description 1
- VXPUPUUTEBJKQY-UHFFFAOYSA-N CCN(CCCOc(ccc1c2N=C(NC(c3cccnc3)=O)N3C1=NCC3)c2OC)CC=C Chemical compound CCN(CCCOc(ccc1c2N=C(NC(c3cccnc3)=O)N3C1=NCC3)c2OC)CC=C VXPUPUUTEBJKQY-UHFFFAOYSA-N 0.000 description 1
- XKVDGFQUQVVMRN-UHFFFAOYSA-N CCN1CCOC(COC2=CC=C3C4=NCCN4C(NC(=O)C4=CC=CN=C4)=NC3=C2OC)C1 Chemical compound CCN1CCOC(COC2=CC=C3C4=NCCN4C(NC(=O)C4=CC=CN=C4)=NC3=C2OC)C1 XKVDGFQUQVVMRN-UHFFFAOYSA-N 0.000 description 1
- TYULJIJXADJVGN-UHFFFAOYSA-N CCNC(=O)NC1=CC=C(C(=O)NC2=NC3=C(OC)C(OCCCN4CCOCC4)=CC=C3C3=NCCN23)C=N1 Chemical compound CCNC(=O)NC1=CC=C(C(=O)NC2=NC3=C(OC)C(OCCCN4CCOCC4)=CC=C3C3=NCCN23)C=N1 TYULJIJXADJVGN-UHFFFAOYSA-N 0.000 description 1
- CSELYIGKBZPLAB-UHFFFAOYSA-N CCNC1=NC(C(=O)NC2=NC3=C(OC)C(OCCCN4CCOCC4)=CC=C3C3=NCCN23)=CS1 Chemical compound CCNC1=NC(C(=O)NC2=NC3=C(OC)C(OCCCN4CCOCC4)=CC=C3C3=NCCN23)=CS1 CSELYIGKBZPLAB-UHFFFAOYSA-N 0.000 description 1
- ASCRMKKLNXDVKE-UHFFFAOYSA-N CNC(=O)NC1=CC=C(C(=O)NC2=NC3=C(OC)C(OCCCN4CCOCC4)=CC=C3C3=NCCN23)C=N1 Chemical compound CNC(=O)NC1=CC=C(C(=O)NC2=NC3=C(OC)C(OCCCN4CCOCC4)=CC=C3C3=NCCN23)C=N1 ASCRMKKLNXDVKE-UHFFFAOYSA-N 0.000 description 1
- BYQRULUQVLMQBK-UHFFFAOYSA-N CNC1=NC=C(C(=O)NC2=NC3=C(OC)C(OCCCN4CCOCC4)=CC=C3C3=NCCN23)C=N1 Chemical compound CNC1=NC=C(C(=O)NC2=NC3=C(OC)C(OCCCN4CCOCC4)=CC=C3C3=NCCN23)C=N1 BYQRULUQVLMQBK-UHFFFAOYSA-N 0.000 description 1
- PUKCESPXCWGTSN-UHFFFAOYSA-N CNCCCOC1=CC=C2C3=NCCN3C(NC(=O)C3=CC=CN=C3)=NC2=C1OC Chemical compound CNCCCOC1=CC=C2C3=NCCN3C(NC(=O)C3=CC=CN=C3)=NC2=C1OC PUKCESPXCWGTSN-UHFFFAOYSA-N 0.000 description 1
- CAQROJOOMXZTPL-UHFFFAOYSA-N COC1=C(N)C(C#N)=CC=C1OCC1=CC=CC=C1 Chemical compound COC1=C(N)C(C#N)=CC=C1OCC1=CC=CC=C1 CAQROJOOMXZTPL-UHFFFAOYSA-N 0.000 description 1
- XRVBOUAQFSGOFT-UHFFFAOYSA-N COC1=C(N)C(C#N)=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C(N)C(C#N)=CC=C1OCCCN1CCOCC1 XRVBOUAQFSGOFT-UHFFFAOYSA-N 0.000 description 1
- RFLYNKLBDDVAJL-UHFFFAOYSA-N COC1=C(N)C(C2=NCCN2)=CC=C1OCC1=CC=CC=C1 Chemical compound COC1=C(N)C(C2=NCCN2)=CC=C1OCC1=CC=CC=C1 RFLYNKLBDDVAJL-UHFFFAOYSA-N 0.000 description 1
- ZROYKUBDBPTBSM-UHFFFAOYSA-N COC1=C(N)C(C2=NCCN2)=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C(N)C(C2=NCCN2)=CC=C1OCCCN1CCOCC1 ZROYKUBDBPTBSM-UHFFFAOYSA-N 0.000 description 1
- HEMPYISMRTXHJH-UHFFFAOYSA-N COC1=C([N+](=O)[O-])C(C#N)=CC=C1O Chemical compound COC1=C([N+](=O)[O-])C(C#N)=CC=C1O HEMPYISMRTXHJH-UHFFFAOYSA-N 0.000 description 1
- JIBYLEHMPLQLTB-UHFFFAOYSA-N COC1=C([N+](=O)[O-])C(C#N)=CC=C1OCC1=CC=CC=C1 Chemical compound COC1=C([N+](=O)[O-])C(C#N)=CC=C1OCC1=CC=CC=C1 JIBYLEHMPLQLTB-UHFFFAOYSA-N 0.000 description 1
- SSUVMPBASIJFQF-UHFFFAOYSA-N COC1=C([N+](=O)[O-])C(C#N)=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C([N+](=O)[O-])C(C#N)=CC=C1OCCCN1CCOCC1 SSUVMPBASIJFQF-UHFFFAOYSA-N 0.000 description 1
- OOKZPTFFKVIJEJ-UHFFFAOYSA-N COC1=C2/N=C(/NC(=O)C3=CN=C(CCN4CCCC4)C=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2/N=C(/NC(=O)C3=CN=C(CCN4CCCC4)C=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 OOKZPTFFKVIJEJ-UHFFFAOYSA-N 0.000 description 1
- NNYLEQRGZWSNKY-UHFFFAOYSA-N COC1=C2/N=C(/NC(=O)C3=CN=C(NC4CCCC4)C=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2/N=C(/NC(=O)C3=CN=C(NC4CCCC4)C=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 NNYLEQRGZWSNKY-UHFFFAOYSA-N 0.000 description 1
- CHHRXHIPJQLXOV-UHFFFAOYSA-N COC1=C2N=C(N)N3CCN=C3C2=CC=C1O Chemical compound COC1=C2N=C(N)N3CCN=C3C2=CC=C1O CHHRXHIPJQLXOV-UHFFFAOYSA-N 0.000 description 1
- LLAWQTBLVDDAPS-UHFFFAOYSA-N COC1=C2N=C(N)N3CCN=C3C2=CC=C1OCC1=CC=CC=C1 Chemical compound COC1=C2N=C(N)N3CCN=C3C2=CC=C1OCC1=CC=CC=C1 LLAWQTBLVDDAPS-UHFFFAOYSA-N 0.000 description 1
- VLPUKEZMPQNOHW-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=C(C)N=C(C)S3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=C(C)N=C(C)S3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 VLPUKEZMPQNOHW-UHFFFAOYSA-N 0.000 description 1
- LTQFHGCERMMMMZ-IYBDPMFKSA-N COC1=C2N=C(NC(=O)C3=C(C)N=C(C)S3)N3CCN=C3C2=CC=C1OCCCN1C[C@H](C)O[C@H](C)C1 Chemical compound COC1=C2N=C(NC(=O)C3=C(C)N=C(C)S3)N3CCN=C3C2=CC=C1OCCCN1C[C@H](C)O[C@H](C)C1 LTQFHGCERMMMMZ-IYBDPMFKSA-N 0.000 description 1
- IGDWQPUGKSBEED-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=C(C)N=C(C)S3)N3CCN=C3C2=CC=C1OCCN(C)C Chemical compound COC1=C2N=C(NC(=O)C3=C(C)N=C(C)S3)N3CCN=C3C2=CC=C1OCCN(C)C IGDWQPUGKSBEED-UHFFFAOYSA-N 0.000 description 1
- NFNLEBOQOSHXAE-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=C(C)N=C(N)S3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=C(C)N=C(N)S3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 NFNLEBOQOSHXAE-UHFFFAOYSA-N 0.000 description 1
- AISRYFOCHNNCSD-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC(Br)=C(N)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CC(Br)=C(N)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 AISRYFOCHNNCSD-UHFFFAOYSA-N 0.000 description 1
- PFWKTIUWQLRPKO-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=C(C(F)(F)F)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CC=C(C(F)(F)F)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 PFWKTIUWQLRPKO-UHFFFAOYSA-N 0.000 description 1
- WCRDAUWROGEPIU-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=C(C)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CC=C(C)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 WCRDAUWROGEPIU-UHFFFAOYSA-N 0.000 description 1
- VCKCXOILCNBEEI-KDURUIRLSA-N COC1=C2N=C(NC(=O)C3=CC=C(C)N=C3)N3CCN=C3C2=CC=C1OCCCN1C[C@H](C)O[C@H](C)C1 Chemical compound COC1=C2N=C(NC(=O)C3=CC=C(C)N=C3)N3CCN=C3C2=CC=C1OCCCN1C[C@H](C)O[C@H](C)C1 VCKCXOILCNBEEI-KDURUIRLSA-N 0.000 description 1
- NERBKHJYFIIREY-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=C(F)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CC=C(F)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 NERBKHJYFIIREY-UHFFFAOYSA-N 0.000 description 1
- FQLSOPBUQUAWQU-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=C(N(C)C)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CC=C(N(C)C)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 FQLSOPBUQUAWQU-UHFFFAOYSA-N 0.000 description 1
- XCNKUTBPMLZWGY-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=C(N)N=C3)N3CCN=C3C2=CC=C1OCCCN(C)C Chemical compound COC1=C2N=C(NC(=O)C3=CC=C(N)N=C3)N3CCN=C3C2=CC=C1OCCCN(C)C XCNKUTBPMLZWGY-UHFFFAOYSA-N 0.000 description 1
- RQZWVQZCWUTKEF-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=C(N)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CC=C(N)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 RQZWVQZCWUTKEF-UHFFFAOYSA-N 0.000 description 1
- LINPBIOHOVOQDG-CALCHBBNSA-N COC1=C2N=C(NC(=O)C3=CC=C(N)N=C3)N3CCN=C3C2=CC=C1OCCCN1C[C@H](C)O[C@H](C)C1 Chemical compound COC1=C2N=C(NC(=O)C3=CC=C(N)N=C3)N3CCN=C3C2=CC=C1OCCCN1C[C@H](C)O[C@H](C)C1 LINPBIOHOVOQDG-CALCHBBNSA-N 0.000 description 1
- PRGHVANXJBUMMP-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=C(N)N=C3C)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CC=C(N)N=C3C)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 PRGHVANXJBUMMP-UHFFFAOYSA-N 0.000 description 1
- PSFJIUNJZQXIQR-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=C(N4C=CC=C4)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CC=C(N4C=CC=C4)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 PSFJIUNJZQXIQR-UHFFFAOYSA-N 0.000 description 1
- ZWIHOWYOWLAPOW-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=C(N4CCCC4)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CC=C(N4CCCC4)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 ZWIHOWYOWLAPOW-UHFFFAOYSA-N 0.000 description 1
- LJUSYJQMLGHWEA-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=C(N4CCNCC4)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1.Cl Chemical compound COC1=C2N=C(NC(=O)C3=CC=C(N4CCNCC4)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1.Cl LJUSYJQMLGHWEA-UHFFFAOYSA-N 0.000 description 1
- ZXCNANBQFAZDKF-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=C(N4CCOCC4)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CC=C(N4CCOCC4)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 ZXCNANBQFAZDKF-UHFFFAOYSA-N 0.000 description 1
- LQLQKCGNICXNHX-HXUWFJFHSA-N COC1=C2N=C(NC(=O)C3=CC=C(N4CC[C@@H](N)C4)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1.Cl Chemical compound COC1=C2N=C(NC(=O)C3=CC=C(N4CC[C@@H](N)C4)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1.Cl LQLQKCGNICXNHX-HXUWFJFHSA-N 0.000 description 1
- REFOWCDYGHQQBV-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=C(NC(=O)C(C)(C)C)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CC=C(NC(=O)C(C)(C)C)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 REFOWCDYGHQQBV-UHFFFAOYSA-N 0.000 description 1
- HFTTWQRPAPPSMP-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=C(NC(=O)C(C)C)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CC=C(NC(=O)C(C)C)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 HFTTWQRPAPPSMP-UHFFFAOYSA-N 0.000 description 1
- IXJJHOVBOPTALF-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=C(NC(=O)C4CC4)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CC=C(NC(=O)C4CC4)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 IXJJHOVBOPTALF-UHFFFAOYSA-N 0.000 description 1
- FENNOTKNLALWMI-HDICACEKSA-N COC1=C2N=C(NC(=O)C3=CC=C(NC(C)=O)N=C3)N3CCN=C3C2=CC=C1OCCCN1C[C@H](C)O[C@H](C)C1 Chemical compound COC1=C2N=C(NC(=O)C3=CC=C(NC(C)=O)N=C3)N3CCN=C3C2=CC=C1OCCCN1C[C@H](C)O[C@H](C)C1 FENNOTKNLALWMI-HDICACEKSA-N 0.000 description 1
- ZFEAQIRTPVZIBC-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=C(NCC4=CC=C(F)C=C4)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CC=C(NCC4=CC=C(F)C=C4)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 ZFEAQIRTPVZIBC-UHFFFAOYSA-N 0.000 description 1
- NLCFWQWMBDPLQU-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=C(NCC4=CC=CO4)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CC=C(NCC4=CC=CO4)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 NLCFWQWMBDPLQU-UHFFFAOYSA-N 0.000 description 1
- RUIMLFLXZSWEAB-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=C(OCC(F)(F)F)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CC=C(OCC(F)(F)F)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 RUIMLFLXZSWEAB-UHFFFAOYSA-N 0.000 description 1
- PWMZGYDCBMLKBJ-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1O Chemical compound COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1O PWMZGYDCBMLKBJ-UHFFFAOYSA-N 0.000 description 1
- MYMPXECESABCMG-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCC1=CC=CC=C1 Chemical compound COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCC1=CC=CC=C1 MYMPXECESABCMG-UHFFFAOYSA-N 0.000 description 1
- IWNNQCNMNDPRNM-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCC1CNCCO1 Chemical compound COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCC1CNCCO1 IWNNQCNMNDPRNM-UHFFFAOYSA-N 0.000 description 1
- ZXMDBQWYACKEDP-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCCC1CCCCO1 Chemical compound COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCCC1CCCCO1 ZXMDBQWYACKEDP-UHFFFAOYSA-N 0.000 description 1
- QYRHNCUQZAEPBK-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCCC1CN(C(=O)OC(C)(C)C)CCO1 Chemical compound COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCCC1CN(C(=O)OC(C)(C)C)CCO1 QYRHNCUQZAEPBK-UHFFFAOYSA-N 0.000 description 1
- BROFTQNYQVPOAG-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCCCC1CN(CC2CCC2)CCO1 Chemical compound COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCCCC1CN(CC2CCC2)CCO1 BROFTQNYQVPOAG-UHFFFAOYSA-N 0.000 description 1
- VVQALBFPGUBIQO-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCCCN(C(C)C)C(C)C Chemical compound COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCCCN(C(C)C)C(C)C VVQALBFPGUBIQO-UHFFFAOYSA-N 0.000 description 1
- SBJDLHJPWPQZLP-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCCCN(C)C Chemical compound COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCCCN(C)C SBJDLHJPWPQZLP-UHFFFAOYSA-N 0.000 description 1
- LVQIMJLFZFIKMA-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCCCN.O=C(O)C(F)(F)F Chemical compound COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCCCN.O=C(O)C(F)(F)F LVQIMJLFZFIKMA-UHFFFAOYSA-N 0.000 description 1
- ZHUXRHRQKUDHHC-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCCCN1CCCCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCCCN1CCCCC1 ZHUXRHRQKUDHHC-UHFFFAOYSA-N 0.000 description 1
- FJLAKZHXRUSKFW-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCCCN1CCN(C)CC1 Chemical compound COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCCCN1CCN(C)CC1 FJLAKZHXRUSKFW-UHFFFAOYSA-N 0.000 description 1
- PTBHOHFIBIMRLB-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 PTBHOHFIBIMRLB-UHFFFAOYSA-N 0.000 description 1
- MBTCIYIPCNTFMO-KRWDZBQOSA-N COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCCCN1CCOC[C@@H]1C Chemical compound COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCCCN1CCOC[C@@H]1C MBTCIYIPCNTFMO-KRWDZBQOSA-N 0.000 description 1
- KUJFQKOTPRLKLL-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCCN Chemical compound COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCCN KUJFQKOTPRLKLL-UHFFFAOYSA-N 0.000 description 1
- HTWHGWBGGRQZIH-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCCN1CCCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCCN1CCCC1 HTWHGWBGGRQZIH-UHFFFAOYSA-N 0.000 description 1
- FTPSRPZIUIMGJG-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCCN1CCCCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCCN1CCCCC1 FTPSRPZIUIMGJG-UHFFFAOYSA-N 0.000 description 1
- VOJJBKFDVYAHHS-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CC=CN=C3)N3CCN=C3C2=CC=C1OCCN1CCOCC1 VOJJBKFDVYAHHS-UHFFFAOYSA-N 0.000 description 1
- LCPXEFLYSZVIKX-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=CS3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CC=CS3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 LCPXEFLYSZVIKX-UHFFFAOYSA-N 0.000 description 1
- AIMJAFTWPZNFBS-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=NC(N)=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CC=NC(N)=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 AIMJAFTWPZNFBS-UHFFFAOYSA-N 0.000 description 1
- HTXHYBJJPFAYJF-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=NC(N)=N3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CC=NC(N)=N3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 HTXHYBJJPFAYJF-UHFFFAOYSA-N 0.000 description 1
- CUZHQMVTVIFZLN-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=NC=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CC=NC=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 CUZHQMVTVIFZLN-UHFFFAOYSA-N 0.000 description 1
- CCLXFYQHHORRCJ-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CC=NC=N3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CC=NC=N3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 CCLXFYQHHORRCJ-UHFFFAOYSA-N 0.000 description 1
- VAUMPSXTRSTNMM-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CN(C)C=N3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CN(C)C=N3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 VAUMPSXTRSTNMM-UHFFFAOYSA-N 0.000 description 1
- LTMJJJRJLOZDKC-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CN=C(N)N=C3)N3CCN=C3C2=CC=C1OCCCN(C)C Chemical compound COC1=C2N=C(NC(=O)C3=CN=C(N)N=C3)N3CCN=C3C2=CC=C1OCCCN(C)C LTMJJJRJLOZDKC-UHFFFAOYSA-N 0.000 description 1
- NZOFGIMATUBYTC-IYBDPMFKSA-N COC1=C2N=C(NC(=O)C3=CN=C(N)N=C3)N3CCN=C3C2=CC=C1OCCCN1C[C@H](C)O[C@H](C)C1 Chemical compound COC1=C2N=C(NC(=O)C3=CN=C(N)N=C3)N3CCN=C3C2=CC=C1OCCCN1C[C@H](C)O[C@H](C)C1 NZOFGIMATUBYTC-IYBDPMFKSA-N 0.000 description 1
- JVNVQISIPQMGQT-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CN=C(N)N=C3C)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CN=C(N)N=C3C)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 JVNVQISIPQMGQT-UHFFFAOYSA-N 0.000 description 1
- AQMSKYKATADCTL-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CN=C(N)O3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CN=C(N)O3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 AQMSKYKATADCTL-UHFFFAOYSA-N 0.000 description 1
- RVGIQILERKVUPZ-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CN=C(N)S3)N3CCN=C3C2=CC=C1OCCCN(C)C Chemical compound COC1=C2N=C(NC(=O)C3=CN=C(N)S3)N3CCN=C3C2=CC=C1OCCCN(C)C RVGIQILERKVUPZ-UHFFFAOYSA-N 0.000 description 1
- RWCMUSCEPMWINC-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CN=C(N)S3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CN=C(N)S3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 RWCMUSCEPMWINC-UHFFFAOYSA-N 0.000 description 1
- JLKWVDHZVRQTKD-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CN=C(N4CCCC4)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CN=C(N4CCCC4)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 JLKWVDHZVRQTKD-UHFFFAOYSA-N 0.000 description 1
- NAEZHLXJNJXOAL-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CN=C(N4CCN(C)CC4)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CN=C(N4CCN(C)CC4)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 NAEZHLXJNJXOAL-UHFFFAOYSA-N 0.000 description 1
- GEPRBHREQZSKPV-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CN=C(NCCCN4CCOCC4)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CN=C(NCCCN4CCOCC4)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 GEPRBHREQZSKPV-UHFFFAOYSA-N 0.000 description 1
- FBVSRQHOALUWEL-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CN=C(NCCN(C)C)N=C3)N3CCN=C3C2=CC=C1OCCCN(C)C Chemical compound COC1=C2N=C(NC(=O)C3=CN=C(NCCN(C)C)N=C3)N3CCN=C3C2=CC=C1OCCCN(C)C FBVSRQHOALUWEL-UHFFFAOYSA-N 0.000 description 1
- LIEXRQYJPIVUTI-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CN=C(NCCN(C)C)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CN=C(NCCN(C)C)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 LIEXRQYJPIVUTI-UHFFFAOYSA-N 0.000 description 1
- AWEMTJCLIYBJLT-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CN=C(NCCO)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CN=C(NCCO)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 AWEMTJCLIYBJLT-UHFFFAOYSA-N 0.000 description 1
- HDDPWQKZPMPNNJ-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CN=C(SC)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CN=C(SC)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 HDDPWQKZPMPNNJ-UHFFFAOYSA-N 0.000 description 1
- BQDLTRWPXDTWFK-HDICACEKSA-N COC1=C2N=C(NC(=O)C3=CN=CC=C3)N3CCN=C3C2=CC=C1OCCCN1C[C@H](C)O[C@H](C)C1 Chemical compound COC1=C2N=C(NC(=O)C3=CN=CC=C3)N3CCN=C3C2=CC=C1OCCCN1C[C@H](C)O[C@H](C)C1 BQDLTRWPXDTWFK-HDICACEKSA-N 0.000 description 1
- XPFWLKBNULVZGM-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CN=CN3C)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CN=CN3C)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 XPFWLKBNULVZGM-UHFFFAOYSA-N 0.000 description 1
- GSSJVBVNMHGKNY-CALCHBBNSA-N COC1=C2N=C(NC(=O)C3=CN=CN=C3)N3CCN=C3C2=CC=C1OCCCN1C[C@H](C)O[C@H](C)C1 Chemical compound COC1=C2N=C(NC(=O)C3=CN=CN=C3)N3CCN=C3C2=CC=C1OCCCN1C[C@H](C)O[C@H](C)C1 GSSJVBVNMHGKNY-CALCHBBNSA-N 0.000 description 1
- XYVNDTVSILQGKM-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CN=CN=C3)N3CCN=C3C2=CC=C1OCCN(C)C Chemical compound COC1=C2N=C(NC(=O)C3=CN=CN=C3)N3CCN=C3C2=CC=C1OCCN(C)C XYVNDTVSILQGKM-UHFFFAOYSA-N 0.000 description 1
- LNMCRSJMLGCLCZ-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=COC(N)=N3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=COC(N)=N3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 LNMCRSJMLGCLCZ-UHFFFAOYSA-N 0.000 description 1
- HERHMVXJRQROEC-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=COC=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=COC=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 HERHMVXJRQROEC-UHFFFAOYSA-N 0.000 description 1
- SGKLUDAKPNLYEE-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CSC(C)=N3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CSC(C)=N3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 SGKLUDAKPNLYEE-UHFFFAOYSA-N 0.000 description 1
- HAMKTMLNCPASGR-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=CSC=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=CSC=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 HAMKTMLNCPASGR-UHFFFAOYSA-N 0.000 description 1
- UXZUCNFZABXJTO-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=C[N+]([O-])=CC=C3)N3CCN=C3C2=CC=C1O Chemical compound COC1=C2N=C(NC(=O)C3=C[N+]([O-])=CC=C3)N3CCN=C3C2=CC=C1O UXZUCNFZABXJTO-UHFFFAOYSA-N 0.000 description 1
- RMCBSODUXRAFGD-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=C[N+]([O-])=CC=C3)N3CCN=C3C2=CC=C1OCC1=CC=CC=C1 Chemical compound COC1=C2N=C(NC(=O)C3=C[N+]([O-])=CC=C3)N3CCN=C3C2=CC=C1OCC1=CC=CC=C1 RMCBSODUXRAFGD-UHFFFAOYSA-N 0.000 description 1
- VSBKXPZKOULKMN-UHFFFAOYSA-N COC1=C2N=C(NC(=O)C3=NC=CN=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 Chemical compound COC1=C2N=C(NC(=O)C3=NC=CN=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1 VSBKXPZKOULKMN-UHFFFAOYSA-N 0.000 description 1
- MSAVTRLRJABLLA-UHFFFAOYSA-N COC1=CC=C(C(=O)NC2=NC3=C(OC)C(OCCCN4CCOCC4)=CC=C3C3=NCCN23)C=N1 Chemical compound COC1=CC=C(C(=O)NC2=NC3=C(OC)C(OCCCN4CCOCC4)=CC=C3C3=NCCN23)C=N1 MSAVTRLRJABLLA-UHFFFAOYSA-N 0.000 description 1
- ZYDGZUAILPRRKM-UHFFFAOYSA-N COC1=CN=CC(C(=O)NC2=NC3=C(OC)C(OCCCN4CCOCC4)=CC=C3C3=NCCN23)=C1 Chemical compound COC1=CN=CC(C(=O)NC2=NC3=C(OC)C(OCCCN4CCOCC4)=CC=C3C3=NCCN23)=C1 ZYDGZUAILPRRKM-UHFFFAOYSA-N 0.000 description 1
- BMALKTLCGJCSFT-UHFFFAOYSA-N COC1=NC=C(C(=O)NC2=NC3=C(OC)C(OCCCN4CCOCC4)=CC=C3C3=NCCN23)C=N1 Chemical compound COC1=NC=C(C(=O)NC2=NC3=C(OC)C(OCCCN4CCOCC4)=CC=C3C3=NCCN23)C=N1 BMALKTLCGJCSFT-UHFFFAOYSA-N 0.000 description 1
- NCJVKJJBGMJLRZ-UHFFFAOYSA-N COCCCNC1=NC=C(C(=O)NC2=NC3=C(OC)C(OCCCN4CCOCC4)=CC=C3C3=NCCN23)C=N1 Chemical compound COCCCNC1=NC=C(C(=O)NC2=NC3=C(OC)C(OCCCN4CCOCC4)=CC=C3C3=NCCN23)C=N1 NCJVKJJBGMJLRZ-UHFFFAOYSA-N 0.000 description 1
- GZVXBDSYVFNCFF-UHFFFAOYSA-N COCCN1CCOC(COC2=CC=C3C4=NCCN4C(NC(=O)C4=CC=CN=C4)=NC3=C2OC)C1 Chemical compound COCCN1CCOC(COC2=CC=C3C4=NCCN4C(NC(=O)C4=CC=CN=C4)=NC3=C2OC)C1 GZVXBDSYVFNCFF-UHFFFAOYSA-N 0.000 description 1
- OEIKWPMVGDLIPD-UHFFFAOYSA-N COCCNC1=CC=C(C(=O)NC2=NC3=C(OC)C(OCCCN4CCOCC4)=CC=C3C3=NCCN23)C=N1 Chemical compound COCCNC1=CC=C(C(=O)NC2=NC3=C(OC)C(OCCCN4CCOCC4)=CC=C3C3=NCCN23)C=N1 OEIKWPMVGDLIPD-UHFFFAOYSA-N 0.000 description 1
- HPLTXEACLZILLB-UHFFFAOYSA-N COCCNC1=NC=C(C(=O)NC2=NC3=C(OC)C(OCCCN4CCOCC4)=CC=C3C3=NCCN23)C=N1 Chemical compound COCCNC1=NC=C(C(=O)NC2=NC3=C(OC)C(OCCCN4CCOCC4)=CC=C3C3=NCCN23)C=N1 HPLTXEACLZILLB-UHFFFAOYSA-N 0.000 description 1
- OFDUIQHTYKILRV-UHFFFAOYSA-N Cl.O=S1OCC(CN2CCOCC2)O1 Chemical compound Cl.O=S1OCC(CN2CCOCC2)O1 OFDUIQHTYKILRV-UHFFFAOYSA-N 0.000 description 1
- PIAZYBLGBSMNLX-UHFFFAOYSA-N ClCCCN1CCOCC1.[H]Cl Chemical compound ClCCCN1CCOCC1.[H]Cl PIAZYBLGBSMNLX-UHFFFAOYSA-N 0.000 description 1
- VLAZLCVSFAYIIL-UHFFFAOYSA-N O=C(O)C(F)(F)F.OCC1CNCCO1 Chemical compound O=C(O)C(F)(F)F.OCC1CNCCO1 VLAZLCVSFAYIIL-UHFFFAOYSA-N 0.000 description 1
- NTZIBYIWQQIOAV-UHFFFAOYSA-N O=C(O)C1=CN=C(NC2CCCC2)C=C1 Chemical compound O=C(O)C1=CN=C(NC2CCCC2)C=C1 NTZIBYIWQQIOAV-UHFFFAOYSA-N 0.000 description 1
- PHCNQUJHXJQLQR-UHFFFAOYSA-N [H]C(=O)C1=CC=C(O)C(OC)=C1[N+](=O)[O-] Chemical compound [H]C(=O)C1=CC=C(O)C(OC)=C1[N+](=O)[O-] PHCNQUJHXJQLQR-UHFFFAOYSA-N 0.000 description 1
- HCFBQKXQWQSMNV-UHFFFAOYSA-N [H]C(=O)C1=CC=C(OC(C)=O)C(OC)=C1[N+](=O)[O-] Chemical compound [H]C(=O)C1=CC=C(OC(C)=O)C(OC)=C1[N+](=O)[O-] HCFBQKXQWQSMNV-UHFFFAOYSA-N 0.000 description 1
- GWLAEBPGTQVKBA-UHFFFAOYSA-N [H]C(=O)C1=CC=C(OCC2=CC=CC=C2)C(OC)=C1[N+](=O)[O-] Chemical compound [H]C(=O)C1=CC=C(OCC2=CC=CC=C2)C(OC)=C1[N+](=O)[O-] GWLAEBPGTQVKBA-UHFFFAOYSA-N 0.000 description 1
- YPOXGDJGKBXRFP-UHFFFAOYSA-N [H]OC(=O)C1=CC=NC=N1 Chemical compound [H]OC(=O)C1=CC=NC=N1 YPOXGDJGKBXRFP-UHFFFAOYSA-N 0.000 description 1
- CBRLWSXYXSFYSP-UHFFFAOYSA-N [H]OC(=O)C1=CN=C(N)N=C1 Chemical compound [H]OC(=O)C1=CN=C(N)N=C1 CBRLWSXYXSFYSP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
- A01N43/54—1,3-Diazines; Hydrogenated 1,3-diazines
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
Definitions
- PI3Ks can be divided into three distinct classes based upon differences in both structure, and substrate preference. While members of the Class II family of PI3Ks have been implicated in the regulation of tumor growth (Brown and Shepard, 2001; Traer et al., 2006), the bulk of research has focused on the Class I enzymes and their role in cancer (Vivanco And Sawyers, 2002; Workman, 2004, Chen et al., 2005; Hennessey et al., 2005; Stauffer et al., 2005; Stephens et al., 2005; Cully et al., 2006).
- Akt phosphorylates and regulates multiple regulatory kinases of pathways that directly influence cell cycle progression and cell survival.
- Akt impacts gene transcription on several levels.
- the Akt-mediated phosphorylation of the MDM2 E3 ubiquitin ligase on Ser 166 and Ser 186 facilitates the nuclear import of MDM2 and the formation and activation of the ubiquitin ligase complex.
- Nuclear MDM2 targets the p53 tumor suppressor for degradation, a process that can be blocked by LY294002 (Yap et al., 2000; Ogarawa et al., 2002). Downregulation of p53 by MDM2 negatively impacts the transcription of p53-regulated pro-apoptotic genes (e.g.
- GSK3 activity is elevated in quiescent cells, where it phosphorylates cyclin D 1 on Ser 286 , targeting the protein for ubiquitination and degradation (Diehl et al., 1998) and blocking entry into S-phase.
- Akt inhibits GSK3 activity through phosphorylation on Ser 9 (Cross et al., 1995). This results in the elevation of Cyclin D 1 levels which promotes cell cycle progression.
- the invention encompasses the compound of Formula (I), wherein R 2 is pyridine, pyridazine, pyrimidine, pyrazine, pyrole, oxazole, thiazole, furan or thiophene, optionally substituted with 1, 2 or 3 R 6 groups; more preferably pyridine, pyridazine, pyrimidine, pyrazine, pyrole, oxazole or thiazole, optionally substituted with 1, 2 or 3 R 6 groups.
- the invention encompasses a compound having the formula:
- alkoxyakyl denotes an alkoxy group as defined herein attached via oxygen linkage to an alkyl group which is then attached to the main structure at any carbon from alkyl group that results in the creation of a stable structure the rest of the molecule.
- Representative examples of those groups are —CH 2 OCH 3 , —CH 2 OC 2 H 5 .
- arylalkyl refers to an aryl group as defined herein directly bonded to an alkyl group as defined herein which is then attached to the main structure at any carbon from alkyl group that results in the creation of a stable structure the rest of the molecule. e.g., —CH 2 C 6 H 5 , —C 2 H 5 C 6 H 5 .
- heterocyclic ring refers to a stable 3- to 15 membered ring radical which consists of carbon atoms and from one to five heteroatoms selected from the group consisting of nitrogen, phosphorus, oxygen and sulfur.
- the heterocyclic ring radical may be a monocyclic, bicyclic or tricyclic ring system, which may include fused, bridged or spiro ring systems, and the nitrogen, phosphorus, carbon, oxygen or sulfur atoms in the heterocyclic ring radical may be optionally oxidized to various oxidation states.
- the nitrogen atom may be optionally quaternized; and the ring radical may be partially or fully saturated (i.e., heteroaromatic or heteroaryl aromatic).
- heteroaryl refers to heterocyclic ring radical as defined herein which are aromatic.
- the heteroaryl ring radical may be attached to the main structure at any heteroatom or carbon atom that results in the creation of a stable structure.
- the heterocyclic ring radical may be attached to the main structure at any heteroatom or carbon atom that results in the creation of a stable structure.
- heterocyclyl refers to a heterocylic ring radical as defined herein.
- the heterocylyl ring radical may be attached to the main structure at any heteroatom or carbon atom that results in the creation of a stable structure.
- heterocyclylalkyl refers to a heterocylic ring radical as defined herein directly bonded to alkyl group.
- the heterocyclylalkyl radical may be attached to the main structure at carbon atom in the alkyl group that results in the creation of a stable structure.
- Pharmaceutically acceptable salts include those obtained by reacting the main compound, functioning as a base, with an inorganic or organic acid to form a salt, for example, salts of hydrochloric acid, sulfuric acid, phosphoric acid, methane sulfonic acid, camphor sulfonic acid, oxalic acid, maleic acid, succinic acid and citric acid.
- Pharmaceutically acceptable salts also include those in which the main compound functions as an acid and is reacted with an appropriate base to form, e.g., sodium, potassium, calcium, magnesium, ammonium, and chorine salts.
- a solvate for the purpose of this invention is a complex of a solvent and a compound of the invention in the solid state.
- Exemplary solvates would include, but are not limited to, complexes of a compound of the invention with ethanol or methanol. Hydrates are a specific form of solvate wherein the solvent is water.
- the pharmaceutical compositions of this invention may also be in the form of oil-in-water emulsions.
- the oily phase may be a vegetable oil such as liquid paraffin or a mixture of vegetable oils.
- Suitable emulsifying agents may be (1) naturally occurring gums such as gum acacia and gum tragacanth, (2) naturally occurring phosphatides such as soy bean and lecithin, (3) esters or partial esters derived form fatty acids and hexitol anhydrides, for example, sorbitan monooleate, (4) condensation products of said partial esters with ethylene oxide, for example, polyoxyethylene sorbitan monooleate.
- the emulsions may also contain sweetening and flavoring agents.
- compositions of this invention will typically contain from about 0.5% to about 25% by weight of the active ingredient in solution. Preservatives and buffers may also be used advantageously. In order to minimize or eliminate irritation at the site of injection, such compositions may contain a non-ionic surfactant having a hydrophile-lipophile balance (HLB) preferably of from about 12 to about 17. The quantity of surfactant in such formulation preferably ranges from about 5% to about 15% by weight.
- the surfactant can be a single component having the above HLB or can be a mixture of two or more components having the desired HLB.
- the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent.
- Diluents and solvents that may be employed are, for example, water, Ringer's solution, isotonic sodium chloride solutions and isotonic glucose solutions.
- sterile fixed oils are conventionally employed as solvents or suspending media.
- any bland, fixed oil may be employed including synthetic mono- or diglycerides.
- fatty acids such as oleic acid can be used in the preparation of injectables.
- compositions of the invention can also contain other conventional pharmaceutically acceptable compounding ingredients, generally referred to as carriers or diluents, as necessary or desired.
- Conventional procedures for preparing such compositions in appropriate dosage forms can be utilized. Such ingredients and procedures include those described in the following references, each of which is incorporated herein by reference: Powell, M. F. et al, “Compendium of Excipients for Parenteral Formulations” PDA Journal of Pharmaceutical Science & Technology 1998, 52(5), 238-311; Strickley, R. G “Parenteral Formulations of Small Molecule Therapeutics Marketed in the United States (1999)-Part-1 ” PDA Journal of Pharmaceutical Science & Technology 1999, 53(6), 324-349; and Nema, S. et al, “Excipients and Their Use in Injectable Products” PDA Journal of Pharmaceutical Science & Technology 1997, 51(4), 166-171.
- acidifying agents examples include but are not limited to acetic acid, citric acid, fumaric acid, hydrochloric acid, nitric acid
- alkalinizing agents examples include but are not limited to ammonia solution, ammonium carbonate, diethanolamine, monoethanolamine, potassium hydroxide, sodium borate, sodium carbonate, sodium hydroxide, triethanolamine, trolamine
- adsorbents examples include but are not limited to powdered cellulose and activated charcoal
- aerosol propellants examples include but are not limited to carbon dioxide, CCl 2 F 2 , F 2 ClC—CClF 2 and CClF 3
- air displacement agents examples include but are not limited to nitrogen and argon
- antifungal preservatives examples include but are not limited to benzoic acid, butylparaben, ethylparaben, methylparaben, propylparaben, sodium benzoate
- antimicrobial preservatives examples include but are not limited to benzoic acid, butylpara
- Sterile IV Solution A 5 mg/mL solution of the desired compound of this invention can be made using sterile, injectable water, and the pH is adjusted if necessary. The solution is diluted for administration to 1-2 mg/mL with sterile 5% dextrose and is administered as an IV infusion over about 60 minutes.
- Lyophilized powder for IV administration A sterile preparation can be prepared with (i) 100-1000 mg of the desired compound of this invention as a lypholized powder, (ii) 32-327 mg/mL sodium citrate, and (iii) 300-3000 mg Dextran 40.
- aqueous and non-aqueous coatings may be applied to increase palatability, improve elegance and stability or delay absorption.
- Immediate Release Tablets/Capsules These are solid oral dosage forms made by conventional and novel processes. These units are taken orally without water for immediate dissolution and delivery of the medication.
- the active ingredient is mixed in a liquid containing ingredient such as sugar, gelatin, pectin and sweeteners. These liquids are solidified into solid tablets or caplets by freeze drying and solid state extraction techniques.
- the drug compounds may be compressed with viscoelastic and thermoelastic sugars and polymers or effervescent components to produce porous matrices intended for immediate release, without the need of water.
- cancers of the respiratory tract include, but are not limited to small-cell and non-small-cell lung carcinoma, as well as bronchial adenoma and pleuropulmonary blastoma.
- Leukemias include, but are not limited to acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and hairy cell leukemia.
- Inappropriate and ectopic expression of angiogenesis can be deleterious to an organism.
- a number of pathological conditions are associated with the growth of extraneous blood vessels. These include, e.g., diabetic retinopathy, ischemic retinal-vein occlusion, and retinopathy of prematurity (Aiello et al. New Engl. J. Med. 1994, 331, 1480; Peer et al. Lab. Invest. 1995, 72, 638), age-related macular degeneration (AMD; see, Lopez et al. Invest. Opththalmol. Vis. Sci.
- neovascular glaucoma neovascular glaucoma, psoriasis, retrolental fibroplasias, angiofibroma, inflammation, rheumatoid arthritis (RA), restenosis, in-stent restenosis, vascular graft restenosis, etc.
- RA rheumatoid arthritis
- restenosis in-stent restenosis
- vascular graft restenosis etc.
- the increased blood supply associated with cancerous and neoplastic tissue encourages growth, leading to rapid tumor enlargement and metastasis.
- the growth of new blood and lymph vessels in a tumor provides an escape route for renegade cells, encouraging metastasis and the consequence spread of the cancer.
- the average daily dosage for administration by injection will preferably be from 0.01 to 200 mg/kg of total body weight.
- the average daily rectal dosage regimen will preferably be from 0.01 to 200 mg/kg of total body weight.
- the average daily vaginal dosage regimen will preferably be from 0.01 to 200 mg/kg of total body weight.
- the average daily topical dosage regimen will preferably be from 0.1 to 200 mg administered between one to four times daily.
- the transdermal concentration will preferably be that required to maintain a daily dose of from 0.01 to 200 mg/kg.
- the average daily inhalation dosage regimen will preferably be from 0.01 to 100 mg/kg of total body weight.
- the compounds of this invention can be administered as the sole pharmaceutical agent or in combination with one or more other pharmaceutical agents where the combination causes no unacceptable adverse effects.
- the compounds of this invention can be combined with known anti-hyper-proliferative, antiinflammatory, analgesic, immunoregulatory, diuretic, antiarrhytmic, anti-hypercholsterolemia, anti-dyslipidemia, anti-diabetic or antiviral agents, and the like, as well as with admixtures and combinations thereof.
- the eluents were A: 2% acetonitrile in water with 0.02% TFA, and B: 2% water in acetonirile with 0.02% TFA. Gradient elution from 10% B to 90% B over 3.0 minutes at a flow rate of 1.0 mL/min was used with an initial hold of 1.0 minutes and a final hold at 95% B of 1.0 minutes. Total run time was 7.0 minutes.
- Alkylation of the phenol in formula (X) can be achieved using a base such as cesium carbonate, sodium hydride, or potassium t-butoxide in a polar aprotic solvent such as DMF or DMSO with introduction of a side chain bearing an appropriate leaving group such as a halide, or a sulfonate group.
- amides of formula (I) can be formed using activated esters such as acid chlorides and anhydrides or alternatively formed using carboxylic acids and appropriate coupling agents such as PYBOP, DCC, or EDCI in polar aprotic solvents.
- the mixture was diluted in THF (20 mL) and treated with a solution of sodium hydroxide (2 N, 5 mL) and stirred overnight.
- the reaction mixture was concentrated under reduced pressure and then diluted with water and EtOAc.
- the pH of the aqueous layer was adjusted to 5, and the organic layer was separated, dried (MgSO 4 ) and concentrated under reduced pressure.
- the solid (2 g, 8.15 mmol) was then dissolved in THF (10 mL) and treated with a borane solution (1 M in THF, 16 mL, 16.4 mmol) and the mixture stirred at rt for 12 h.
- the reaction mixture was then diluted with methanol (100 mL) and stirred at rt overnight.
- Morpholin-2-ylmethanol trifluoroacetate (0.7 g, 3.03 mmol) in DCM was treated with triethylamine (1.67 mL, 12.1 mmol) and tert-butyldimethylsilyl chloride (0.91 g, 6.06 mmol). The mixture was stirred at rt for 2 h and then filtered. The filtrate was then concentrated under reduced pressure and the residue was suspended in a dilute solution of sodium hydroxide (10%, 5 mL), and the mixture was stirred for 30 min. The mixture was then extracted with DCM and concentrated under reduced pressure to a foam.
- 3-Morpholin-4-ylpropane-1,2-diol (2.1 g, 9.07 mmol) was dissolved in DCM (15 mL) and cooled to 0° C. The cooled solution was treated with thionyl chloride (1.81 mL, 24.8 mmol) and then heated at the reflux temperature for 1 h.
- Step 1 Preparation of 4-formyl-2-methoxy-3-nitrophenyl acetate
- Step 8 Preparation of 5-amino-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-8-ol bis(trifluoroacetate)
- Step 1 Preparation of N-(8- ⁇ 3-[2-( ⁇ [tert-butyl(dimethyl)silyl]oxy ⁇ methyl)morpholin-4-yl]propoxy ⁇ -7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)nicotinamide
- Step 1 Preparation of N-[8-(benzyloxy)-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]nicotinamide 1-oxide
- frugiperda 9 insect cells was obtained from ALEXIS BIOCHEMICALS (#201-055-0010; San Diego, Calif.).
- [ ⁇ 33 P]ATP and unlabeled ATP were purchased from AMERSHAM PHARMACIA B IOTECH (Buckinghamshire, UK) and R OCHE D IAGNOSTICS (Mannheim, Germany), respectively.
- Scintillation cocktails and MicroScint PSTM were purchased from PACKARD (Meriden, Conn.).
- MaxisorpTM plates were purchased from N ALGE N UNC I NTERNATIONAL K.K. (Tokyo, Japan). All other chemicals not further specified were from W AKO P URE C HEMICALS (Osaka, Japan).
- the MaxisorpTM plates were coated with 50 ⁇ L/well of a solution containing 50 mg/ml PtdIns and 50 mg/ml PtdSer dissolved in chloroform:ethanol (3:7). The plates were subsequently air-dried by incubation for at least 2 hours in a fume hood. The reaction was set up by mixing 25 mL/well of assay buffer 2 ⁇ (100 mM MOPSO/NaOH, 0.2 M NaCl, pH 7.0, 8 mM MgCl 2 , 2 mg/mL BSA (fatty acid-free)), and 7.5 ng/well PI3K ⁇ in the lipid pre-coated plate.
- assay buffer 2 ⁇ 100 mM MOPSO/NaOH, 0.2 M NaCl, pH 7.0, 8 mM MgCl 2 , 2 mg/mL BSA (fatty acid-free)
- Each experimental group consisted of 10 nude rats. Compounds were dissolved in a compatible vehicle for both intravenous and oral administration. For intravenous administration of compound, rats were warmed under a heating lamp for 5 minutes, then placed in a restraining device, and injected intravenously via the tail vein using a dosing volume ranging from 2 mL/kg to 5 mL/kg with a sterile 25 gauge needle. Oral dosing utilizes sterile disposable feeding needles (18 gauge/2 inch) from Popper and Sons, New Hyde Park, N.Y. Tumor growth was measured with electronic calipers 2-3 times a week and tumor weight (mg) calculated according to the following formula: [length (mm) ⁇ width (mm)2]/2.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/908,566 US20130261113A1 (en) | 2006-12-05 | 2013-06-03 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87309006P | 2006-12-05 | 2006-12-05 | |
PCT/US2007/024985 WO2008070150A1 (en) | 2006-12-05 | 2007-12-05 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
US51787510A | 2010-12-20 | 2010-12-20 | |
US13/908,566 US20130261113A1 (en) | 2006-12-05 | 2013-06-03 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/517,875 Continuation US8466283B2 (en) | 2006-12-05 | 2007-12-05 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
PCT/US2007/024985 Continuation WO2008070150A1 (en) | 2006-12-05 | 2007-12-05 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
Publications (1)
Publication Number | Publication Date |
---|---|
US20130261113A1 true US20130261113A1 (en) | 2013-10-03 |
Family
ID=39492563
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/398,916 Active 2028-09-15 USRE46856E1 (en) | 2006-12-05 | 2007-12-05 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
US12/517,875 Ceased US8466283B2 (en) | 2006-12-05 | 2007-12-05 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
US13/908,566 Abandoned US20130261113A1 (en) | 2006-12-05 | 2013-06-03 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/398,916 Active 2028-09-15 USRE46856E1 (en) | 2006-12-05 | 2007-12-05 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
US12/517,875 Ceased US8466283B2 (en) | 2006-12-05 | 2007-12-05 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
Country Status (42)
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130317004A1 (en) * | 2010-11-11 | 2013-11-28 | Bayer Intellectual Property Gmbh | Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
US10383877B2 (en) | 2008-09-24 | 2019-08-20 | Bayer Intellectual Property Gmbh | Use of substituted 2, 3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
US10844066B2 (en) | 2016-03-08 | 2020-11-24 | Bayer Pharma Aktiengesellschaft | 2-amino-N-[7-methoxy-2, 3-dihydroimidazo-[1,2-c] quinazolin-5-yl] pyrimidine-5-carboxamides |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2713388C (en) * | 2008-01-14 | 2016-03-29 | William Scott | Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
EP2168582A1 (en) | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines |
ES2614130T3 (es) * | 2008-09-30 | 2017-05-29 | Pfizer Inc. | Compuestos de imidazo[1,5]naftiridina, su uso farmacéutico y composiciones |
EP2184276A1 (en) | 2008-11-07 | 2010-05-12 | Universite Paul Cezanne Aix-Marseille Iii | Process to prepare new substituted 1H-Benzo(d) imidazol-2(3h)-Ones, New intermediates and their use as bace 1 inhibitors |
EP2388252B1 (en) | 2009-01-16 | 2013-07-24 | Daiso Co., Ltd. | Process for producing 2-hydroxymethylmorpholine salt |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
PE20130191A1 (es) * | 2010-04-16 | 2013-02-21 | Bayer Ip Gmbh | Combinaciones que contienen 2, 3-dihidroimidazo[1, 2-c]quinazolina sustituida |
US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
CN103298469A (zh) | 2010-08-31 | 2013-09-11 | 首尔大学校产学协力财团 | PPARδ激动剂的胎儿重编程的用途 |
WO2012062743A1 (en) | 2010-11-11 | 2012-05-18 | Bayer Pharma Aktiengesellschaft | Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-c]quinolines |
CN103339133B (zh) * | 2010-11-11 | 2016-06-15 | 拜耳知识产权有限责任公司 | 烷氧基取代的2,3-二氢咪唑并[1,2-c]喹唑啉 |
EP2508525A1 (en) * | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
JO3733B1 (ar) * | 2011-04-05 | 2021-01-31 | Bayer Ip Gmbh | استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
BR112014031421A2 (pt) | 2012-06-15 | 2017-06-27 | Brigham & Womens Hospital Inc | composições para tratamento de câncer e métodos para produção das mesmas |
EP2914260A1 (en) | 2012-10-31 | 2015-09-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preventing antiphospholipid syndrome (aps) |
SG10201704511RA (en) * | 2012-11-02 | 2017-07-28 | Tg Therapeutics Inc | Combination of anti-cd20 antibody and pi3 kinase selective inhibitor |
CN103214489B (zh) * | 2013-02-25 | 2016-10-26 | 中国人民解放军第二军医大学 | 一类具有抗肿瘤活性的多靶点激酶抑制剂及其制备方法 |
CU24400B1 (es) * | 2013-04-08 | 2019-04-04 | Bayer Pharma AG | Una composición que comprende 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas |
CN104557955B (zh) * | 2013-10-23 | 2017-05-03 | 上海汇伦生命科技有限公司 | 作为PI3K/mTOR抑制剂的三环类化合物,其制备方法和用途 |
US20150148345A1 (en) * | 2013-11-26 | 2015-05-28 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
US10117874B2 (en) | 2013-12-03 | 2018-11-06 | Bayer Pharma Aktiengesellschaft | Combination of PI3K-inhibitors |
WO2015082378A1 (en) | 2013-12-03 | 2015-06-11 | Bayer Pharma Aktiengesellschaft | Combination of pi3k-inhibitors |
TWI533871B (zh) | 2014-03-11 | 2016-05-21 | 國立中央大學 | 萘并[2,3-f]喹喔啉-7,12-二酮化合物緩解疼痛的應用 |
TWI533869B (zh) | 2014-03-11 | 2016-05-21 | 國立中央大學 | 蒽醌[2,1-c][1,2,5]噻二唑-6,11-二酮化合物緩解疼痛的應用 |
FR3018813B1 (fr) * | 2014-03-18 | 2016-04-15 | Maco Pharma Sa | Procede de synthese d'un derive de psoralene |
WO2016059220A1 (en) | 2014-10-16 | 2016-04-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Tcr-activating agents for use in the treatment of t-all |
EP3018127A1 (en) * | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
EP3018131A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
BR112017019188A2 (pt) * | 2015-03-09 | 2018-04-24 | Bayer Pharma Aktiengesellschaft | Combinações contendo 2,3-di-hidroimidazo[1,2-c] quinazolina substituídas |
MX2017011607A (es) * | 2015-03-09 | 2018-04-10 | Bayer Pharma AG | Uso de 2,3-dihidroimidazol[1,2-c]quinazolinas sustituidas. |
FR3033499A1 (fr) * | 2015-03-11 | 2016-09-16 | Centre Leon-Berard | Composition pour le traitement des tumeurs neuroendocrines pancreatiques |
MX2020003415A (es) * | 2015-07-02 | 2021-12-07 | F Hoffmann La Roche Ag | Compuestos de benzoxacepina oxazolidinona y métodos de uso. |
CN105130997B (zh) * | 2015-09-25 | 2017-12-05 | 苏州明锐医药科技有限公司 | 一种库潘尼西的制备方法 |
CN105130998B (zh) * | 2015-09-25 | 2017-07-28 | 苏州立新制药有限公司 | 库潘尼西的制备方法 |
EP3219329A1 (en) | 2016-03-17 | 2017-09-20 | Bayer Pharma Aktiengesellschaft | Combinations of copanlisib |
WO2017205595A1 (en) | 2016-05-26 | 2017-11-30 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Compositions and methods for treating pulmonary vascular disease |
WO2017211248A1 (zh) * | 2016-06-08 | 2017-12-14 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的咪唑并喹唑啉化合物及其药物组合物 |
CA3037626A1 (en) | 2016-09-23 | 2018-03-29 | Bayer Pharma Aktiengesellschaft | Combination of pi3k-inhibitors |
CN106177918A (zh) * | 2016-09-30 | 2016-12-07 | 广州赛莱拉干细胞科技股份有限公司 | 一种间充质干细胞注射液及其制备方法和应用 |
JP2020503289A (ja) | 2016-12-14 | 2020-01-30 | ターベダ セラピューティクス インコーポレイテッドTarveda Therapeutics,Inc. | Hsp90標的化コンジュゲート及びその製剤 |
EP3585437B1 (en) | 2017-02-24 | 2022-12-21 | Bayer Pharma Aktiengesellschaft | Combinations of copanlisib with anti-pd-1 antibody |
WO2018215282A1 (en) | 2017-05-26 | 2018-11-29 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and pi3k inhibitors |
WO2019002068A1 (en) | 2017-06-28 | 2019-01-03 | Bayer Consumer Care Ag | COMBINATION OF A PI3K INHIBITOR AND AN ANDROGEN RECEPTOR ANTAGONIST |
WO2019010491A1 (en) * | 2017-07-07 | 2019-01-10 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | COMBINATIONS OF MEDICINES FOR THE PROTECTION AGAINST THE DEATH OF NEURONAL CELLS |
ES2930081T3 (es) * | 2017-08-11 | 2022-12-07 | Teligene Ltd | Pirazolopirimidinas sustituidas útiles como inhibidores de quinasas |
EP3498266A1 (en) | 2017-12-15 | 2019-06-19 | Bayer Consumer Care AG | Formulations of copanlisib |
DK3678644T3 (da) | 2017-09-08 | 2023-07-31 | Bayer Pharma AG | Formuleringer af copanlisib |
WO2019105734A1 (en) | 2017-11-28 | 2019-06-06 | Bayer Consumer Care Ag | Combinations of copanlisib |
WO2019105835A1 (en) | 2017-11-29 | 2019-06-06 | Bayer Consumer Care Ag | Combinations of copanlisib and anetumab ravtansine |
WO2019197269A1 (en) | 2018-04-11 | 2019-10-17 | Bayer Aktiengesellschaft | Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer |
CN108383849B (zh) * | 2018-04-26 | 2020-11-06 | 浙江大学 | 咪唑并喹唑啉衍生物及其在抗肿瘤抗炎中的应用 |
CN108841318A (zh) * | 2018-07-12 | 2018-11-20 | 中国科学院海洋研究所 | 一种自修复壳聚糖水凝胶防腐涂料及其合成方法 |
WO2020043617A1 (en) | 2018-08-28 | 2020-03-05 | Bayer As | Combination of pi3k-inhibitors and targeted thorium conjugates |
US20210369724A1 (en) | 2018-10-16 | 2021-12-02 | Bayer Aktiengesellschaft | Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds |
CN109516961B (zh) * | 2018-12-25 | 2021-01-01 | 浙江大学 | 氨基喹唑啉酮和氨基异喹啉酮衍生物及其应用 |
WO2020164997A1 (en) | 2019-02-12 | 2020-08-20 | Bayer Aktiengesellschaft | Combination of pi3k-inhibitors |
WO2023139125A1 (en) | 2022-01-18 | 2023-07-27 | Synthon B.V. | Improved process for preparation of copanlisib |
WO2023218032A1 (en) | 2022-05-13 | 2023-11-16 | Synthon B.V. | Solid forms of copanlisib salts |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3644354A (en) | 1968-09-16 | 1972-02-22 | Sandoz Ag | 5-substituted-2 3-dihydroimidazo(1 2-c)quinazolines |
US4146718A (en) | 1978-04-10 | 1979-03-27 | Bristol-Myers Company | Alkyl 5,6-dichloro-3,4-dihydro-2(1h)-iminoquinazoline-3-acetate hydrohalides |
JP3729343B2 (ja) * | 2000-04-27 | 2005-12-21 | アステラス製薬株式会社 | 縮合ヘテロアリール誘導体 |
US6608053B2 (en) * | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
PA8578001A1 (es) * | 2002-08-07 | 2004-05-07 | Warner Lambert Co | Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas |
JP4790266B2 (ja) * | 2002-09-30 | 2011-10-12 | バイエル・シエリング・フアーマ・アクチエンゲゼルシヤフト | 縮合アゾールピリミジン誘導体 |
AT412873B (de) | 2004-02-20 | 2005-08-25 | Aop Orphan Pharmaceuticals Ag | Verfahren zur herstellung von anagrelid hydrochlorid |
WO2007143483A2 (en) | 2006-06-01 | 2007-12-13 | Smithkline Beecham Corporation | Combination of pazopanib and lapatinib for treating cancer |
WO2008002039A1 (en) | 2006-06-28 | 2008-01-03 | Hanmi Pharm. Co., Ltd. | Quinazoline derivatives for inhibiting the growth of cancer cell |
EP2508525A1 (en) | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
-
2007
- 2007-12-03 AR ARP070105390A patent/AR064106A1/es active IP Right Grant
- 2007-12-04 PA PA20078759601A patent/PA8759601A1/es unknown
- 2007-12-04 TW TW096145999A patent/TWI406662B/zh active
- 2007-12-04 JO JOP/2007/0517A patent/JO3147B1/ar active
- 2007-12-04 UY UY30761A patent/UY30761A1/es not_active Application Discontinuation
- 2007-12-04 PE PE2007001709A patent/PE20081444A1/es active IP Right Grant
- 2007-12-05 ES ES07862580T patent/ES2572189T3/es active Active
- 2007-12-05 SI SI200731771A patent/SI2096919T1/sl unknown
- 2007-12-05 PL PL07862580T patent/PL2096919T3/pl unknown
- 2007-12-05 HU HUE07862580A patent/HUE028773T2/en unknown
- 2007-12-05 JP JP2009540293A patent/JP5326092B2/ja active Active
- 2007-12-05 CN CN202211453281.7A patent/CN115724847A/zh active Pending
- 2007-12-05 CN CN200780044849.7A patent/CN101631464B/zh active Active
- 2007-12-05 CA CA2671614A patent/CA2671614C/en active Active
- 2007-12-05 CL CL200703508A patent/CL2007003508A1/es unknown
- 2007-12-05 US US15/398,916 patent/USRE46856E1/en active Active
- 2007-12-05 EP EP07862580.3A patent/EP2096919B1/en active Active
- 2007-12-05 SG SG2011088887A patent/SG177170A1/en unknown
- 2007-12-05 WO PCT/US2007/024985 patent/WO2008070150A1/en active Application Filing
- 2007-12-05 CN CN201510632842.3A patent/CN105254634B/zh active Active
- 2007-12-05 BR BRPI0720178A patent/BRPI0720178B8/pt active IP Right Grant
- 2007-12-05 DK DK07862580.3T patent/DK2096919T3/en active
- 2007-12-05 MY MYPI20092044A patent/MY157944A/en unknown
- 2007-12-05 US US12/517,875 patent/US8466283B2/en not_active Ceased
- 2007-12-05 RS RS20170561A patent/RS56045B1/sr unknown
- 2007-12-05 MX MX2009006001A patent/MX2009006001A/es active IP Right Grant
- 2007-12-05 NZ NZ577342A patent/NZ577342A/en unknown
- 2007-12-05 CN CN201810535933.9A patent/CN108774232B/zh active Active
- 2007-12-05 KR KR1020097011551A patent/KR101501785B1/ko active IP Right Grant
- 2007-12-05 UA UAA200906701A patent/UA96965C2/ru unknown
- 2007-12-05 AU AU2007328008A patent/AU2007328008B2/en active Active
- 2007-12-05 EA EA200900733A patent/EA018839B1/ru not_active IP Right Cessation
-
2009
- 2009-04-13 TN TNP2009000137A patent/TN2009000137A1/fr unknown
- 2009-04-21 IL IL198273A patent/IL198273A/en active IP Right Grant
- 2009-06-04 EC EC2009009387A patent/ECSP099387A/es unknown
- 2009-06-04 CO CO09057915A patent/CO6220908A2/es active IP Right Grant
- 2009-06-04 HN HN2009001131A patent/HN2009001131A/es unknown
- 2009-06-05 GT GT200900154A patent/GT200900154A/es unknown
- 2009-06-05 CR CR10838A patent/CR10838A/es unknown
- 2009-06-05 DO DO2009000135A patent/DOP2009000135A/es unknown
- 2009-06-05 SV SV2009003288A patent/SV2009003288A/es unknown
- 2009-06-05 CU CU20090103A patent/CU23796B7/es active IP Right Grant
- 2009-06-29 MA MA32057A patent/MA31283B1/fr unknown
- 2009-07-03 NO NO20092529A patent/NO342348B1/no unknown
- 2009-07-03 ZA ZA200904691A patent/ZA200904691B/xx unknown
-
2013
- 2013-06-03 US US13/908,566 patent/US20130261113A1/en not_active Abandoned
-
2016
- 2016-05-26 HK HK16106013.2A patent/HK1217953A1/zh unknown
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10383877B2 (en) | 2008-09-24 | 2019-08-20 | Bayer Intellectual Property Gmbh | Use of substituted 2, 3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
US20130317004A1 (en) * | 2010-11-11 | 2013-11-28 | Bayer Intellectual Property Gmbh | Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
US8895549B2 (en) * | 2010-11-11 | 2014-11-25 | Bayer Intellectual Property Gmbh | Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
US9902727B2 (en) | 2010-11-11 | 2018-02-27 | Bayer Intellectual Property Gmbh | Aminoalcohol substituted 2,3-dihydroimidazo[1,2-C]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
US10844066B2 (en) | 2016-03-08 | 2020-11-24 | Bayer Pharma Aktiengesellschaft | 2-amino-N-[7-methoxy-2, 3-dihydroimidazo-[1,2-c] quinazolin-5-yl] pyrimidine-5-carboxamides |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8466283B2 (en) | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
US8859572B2 (en) | Sulfone substituted 2,3-dihydroimidazo [1,2-C] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis | |
US10226469B2 (en) | Use of substituted 2,3-dihydroimidazo[1,2-C]quinazolines for treating lymphomas | |
US8895549B2 (en) | Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
US10202385B2 (en) | Use of substituted 2,3-dihydroimidazo[1,2-C]quinazolines | |
EP2168582A1 (en) | Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BAYER PHARMACEUTICALS CORPORATION, CONNECTICUT Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HENTEMANN, MARTIN, DR;WOOD, JILL, DR.;SCOTT, WILLIAM, DR.;AND OTHERS;SIGNING DATES FROM 20071211 TO 20071216;REEL/FRAME:033018/0960 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |